In:
Cancer Research, American Association for Cancer Research (AACR), Vol. 71, No. 8_Supplement ( 2011-04-15), p. 4300-4300
Abstract:
We have previously developed a telomerase-specific replicating adenovirus expressing GFP (OBP-401). Intraperitoneal (i.p.) injection of OBP-401 specifically labeled peritoneal tumors with GFP enabling real-time surgical navigation. However, technical difficulty of removing microscopic tumors still remains, which makes it difficult to eradicate disease completely, even after so-called complete resection. In this study we report an additional advantage of OBP-401. Weeks after surgical navigation with OBP-401, recurrent tumor nodules were observed with GFP imaging, indicating that OBP-401 treatment for peritoneal disseminated disease enabled detection of its subsequent recurrence after surgical navigation. Thus tumor labeling with a genetic reporter has important advantages over antibody and other non-genetic labeling since reminant disease remains labeled and can be further resected. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4300. doi:10.1158/1538-7445.AM2011-4300
Type of Medium:
Online Resource
ISSN:
0008-5472
,
1538-7445
DOI:
10.1158/1538-7445.AM2011-4300
Language:
English
Publisher:
American Association for Cancer Research (AACR)
Publication Date:
2011
detail.hit.zdb_id:
2036785-5
detail.hit.zdb_id:
1432-1
detail.hit.zdb_id:
410466-3
Bookmarklink